FibroBiologics (FBLG) Registration filing summary

Company overview and business model

• Clinical-stage biotechnology company developing fibroblast-based therapies for chronic diseases, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and human longevity applications.

• Most advanced product candidates are CYWC628, CYPS317, CYMS101, and CybroCell.

• Formed in April 2021, converted to a Delaware corporation in December 2021, with principal offices in Houston, Texas.

Financial performance and metrics

• Historical net tangible book value as of December 31, 2025, was $6.2 million or $1.8509 per share.

• Pro forma as adjusted net tangible book value after the offering would be $11.2 million, or $1.4189 per share.

• Immediate dilution to new investors is $2.9811 per share based on the assumed offering price.

Use of proceeds and capital allocation

• Estimated net proceeds of $4.3 million, assuming no sale of Pre-Funded Warrants and no exercise of Warrants.

• Proceeds intended for working capital and general corporate purposes.

• Management retains broad discretion over the use of proceeds.